| Literature DB >> 21782058 |
Boris A Ratsch1, Michael Grau, Bernd Dörken, Peter Lenz, Georg Lenz.
Abstract
Mantle cell lymphoma (MCL) is characterized by adverse prognosis and the development of novel therapeutic approaches is essential to improve outcome. The introduction of gene expression profiling using DNA microarrays has significantly enhanced our understanding of the molecular pathogenesis of MCL, which is a prerequisite to the development of novel treatment strategies. Gene expression profiling can furthermore be applied to predict treatment response at diagnosis and thus can be used to assess a patient's individual risk profile. This review summarizes our current knowledge on the use of microarray technology in MCL.Entities:
Mesh:
Year: 2011 PMID: 21782058 DOI: 10.1053/j.seminhematol.2011.03.007
Source DB: PubMed Journal: Semin Hematol ISSN: 0037-1963 Impact factor: 3.851